Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OS Therapies Incorporated (OSTX)
:OSTX
OSTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $7.00
Previous CloseN/A
Volume28.07K
Average Volume (3M)850.50K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-2.87
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,533,356
10 Day Avg. Volume2,280,254
30 Day Avg. Volume850,498
Standard Deviation0.60
R-Squared0.49
Alpha0.23
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside665.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessOST-HER2 achieved successful results in a Phase 2b study for recurrent osteosarcoma, meeting the primary endpoint of 12-month event-free survival.
Financial OutlookOn the positive outcome and potential for accelerated approval, the revenue risk adjustment was lowered, increasing the 12-month price target to $15.
Regulatory Approval PotentialThe positive trial data positions OS Therapies to engage with the FDA about filing for accelerated approval.
Bears Say
Approval Timeline UncertaintyApproval timelines remain uncertain with synthetic control and P2b data potentially supporting accelerated approval in 2025 and full approval in 2026.
Cash ReservesThe company has $1.8M in cash and a $15M equity line, which may limit its financial flexibility despite providing runway into the first half of 2026.
Market CompetitionRecurrent osteosarcoma, the initial indication, poses a $1.5B+ market opportunity but faces no standard of care, which may complicate market penetration efforts.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.23%
Insiders
<0.01% Other Institutional Investors
95.75% Public Companies and
Individual Investors
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.58 and its highest was $7.00 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
Currently, no data Available
When is OS Therapies Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OS Therapies Incorporated’s earnings last quarter?
Currently, no data Available
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 21,533,356 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
---
Company Description
OS Therapies Incorporated
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OS Therapies was launched to meet significant unmet need for new treatments in cancers of the bone in kids and adults. Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. At OST, we are trying to answer the calls for new treatments, considering there have been no new treatments for OS in over 30 years. OST has expanded the pipeline beyond Osteosarcoma with OST-HER2 into other solid tumors with the same recurrence mechanism of action, including Breast, Esophageal and Lung cancer. With the addition of OST-tADC, considered a next generation Antibody Drug Conjugate (ADC) platform technology, we will be targeting Ovarian, Lung and Pancreatic cancer.
---
OSTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(665.31% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Abeona Therapeutics
―
Cyclerion Therapeutics
―
ADC Therapeutics
―
Best Analysts Covering OSTX
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-27.20%
reiterated a buy rating 26 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -27.20% per trade.
---